考博英语阅读理解专项练习12

嘎嘣脆

About 14,000 people will contract HIV today. And tomorrow and the day after that, and every day for the foreseeable future. That's 5 million by the end of the year, most of whom will be dead within a decade.
Figure like these bring home the devastating impact of AIDS and the Urgent need of for a cheap, effective vaccine. As a stroke, a vaccine could stop the tide of infection and stem the need for more, costly treatment. If could even help people who already have the virus healthy.
Back in 1990, drugs companies and researchers confidently predicted we'd Have a vaccine against HIV-1 within 10 years. These were rash statement. The virus has turned out to be more cunning and stealthy than anyone expected. And our knowledge of how vaccine boister the immune system hasn't been good enough. A dozen years on, we still have no clear-cut candidate for a vaccine. So you maight expected the announcement of two large-scale trials of AIDS Vaccines to be applauded. Yet they have been criticized as a monumental waste of money. The trials will test almost identical vaccine, neither of which is expected to offer great protection against the virus. What's more. Both are funded by the US government. One through the national Institute of Health and the other through the Department of Defense.
The NIH and the DoD have a long history of rivalry in AIDS research. But in this case it seems sensible for the NIH to back down. Although the NIH is under pressure "to be seen to be doing something", duplicating work of questionable value is itself questionable. Better to join forces with the military for this trail and spend money saved-with amounts to about $60 million-elsewhere.
There are, after all, reasons for optimism. A new wave of vaccine from industry and academia has nearly completed safety tests. It makes sense to carry out limited trials of all this newcomers to identify which ones offer the best protection, before committing tens of millions of dollars to larger trials.
Such a strategy would need the agreement of drugs companies, government Agencies and medical charities-something that's not as Utopian as it sounds. The NIH has already signed a deal to test a new AIDS vaccine made by the Pharmaceuticals giant Merck. And the international AIDS Vaccine Initiative, a not-for-profit funding organization based in New York, had pioneered new ways to divide up intellectual property rights for successful vaccines.
What's needed is cooperation and coordination, not competition. The important thing is to find the fastest route to an effective vaccine. Every day we forget that, another 14,000 people pay the price.

81．Today the tide of HIV infection.
A．drowns 14,000 people
B．calls for a cheap, effective vaccine
C．rolls without any countervailing measure
D．is curbed with an inexpensive, effective vaccine
82．Neither of the vaccine tested in the two large-scale trails ______.
A．is in the right track
B．turned out to be a manufacturer
C．is sufficiently funded for research
D．is capable of inhibiting the tide of HIV infections
83．The author questions ______.
A．The two rivals' intention to back down
B．Insufficient investment in AIDS RESEARCH
C．The two trials testing almost identical vaccines
D．The allocation of funds between the NIH and the DoD
84．According to the passage, it is imperative that ______.
A．the two rivals of AIDS vaccines change their research lines
B．less pressure be imposed upon the NIH and the DoD
C．the NIH joined the DoD
D．all of the above
85．The strategy put forward in the passage implies that ______.
A．rivalries can hamper the fight against AIDS  　　B．there are no shortcuts to conquest over AIDS  　　C．the tide of AIDS infections is not taken seriously enough  　　D．one single institution is enough to turn out an effective vaccine